Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

196 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Protein kinase inhibitors for the treatment of advanced and progressive radiorefractory thyroid tumors: From the clinical trials to the real life.
Matrone A, Valerio L, Pieruzzi L, Giani C, Cappagli V, Lorusso L, Agate L, Puleo L, Viola D, Bottici V, Del Re M, Molinaro E, Danesi R, Elisei R. Matrone A, et al. Among authors: viola d. Best Pract Res Clin Endocrinol Metab. 2017 Jun;31(3):319-334. doi: 10.1016/j.beem.2017.06.001. Epub 2017 Jun 15. Best Pract Res Clin Endocrinol Metab. 2017. PMID: 28911728 Review.
RET genetic screening of sporadic medullary thyroid cancer (MTC) allows the preclinical diagnosis of unsuspected gene carriers and the identification of a relevant percentage of hidden familial MTC (FMTC).
Romei C, Cosci B, Renzini G, Bottici V, Molinaro E, Agate L, Passannanti P, Viola D, Biagini A, Basolo F, Ugolini C, Materazzi G, Pinchera A, Vitti P, Elisei R. Romei C, et al. Among authors: viola d. Clin Endocrinol (Oxf). 2011 Feb;74(2):241-7. doi: 10.1111/j.1365-2265.2010.03900.x. Clin Endocrinol (Oxf). 2011. PMID: 21054478
In silico and in vitro analysis of rare germline allelic variants of RET oncogene associated with medullary thyroid cancer.
Cosci B, Vivaldi A, Romei C, Gemignani F, Landi S, Ciampi R, Tacito A, Molinaro E, Agate L, Bottici V, Cappagli V, Viola D, Piaggi P, Vitti P, Pinchera A, Elisei R. Cosci B, et al. Among authors: viola d. Endocr Relat Cancer. 2011 Sep 20;18(5):603-12. doi: 10.1530/ERC-11-0117. Print 2011 Oct. Endocr Relat Cancer. 2011. PMID: 21810974
Incidental versus clinically evident thyroid cancer: a 5-year follow-up study.
Minuto MN, Miccoli M, Viola D, Ugolini C, Giannini R, Torregrossa L, Antonangeli L, Aghini-Lombardi F, Elisei R, Basolo F, Miccoli P. Minuto MN, et al. Among authors: viola d. Head Neck. 2013 Mar;35(3):408-12. doi: 10.1002/hed.22974. Epub 2012 Feb 24. Head Neck. 2013. PMID: 22367912
Modifications in the papillary thyroid cancer gene profile over the last 15 years.
Romei C, Fugazzola L, Puxeddu E, Frasca F, Viola D, Muzza M, Moretti S, Nicolosi ML, Giani C, Cirello V, Avenia N, Rossi S, Vitti P, Pinchera A, Elisei R. Romei C, et al. Among authors: viola d. J Clin Endocrinol Metab. 2012 Sep;97(9):E1758-65. doi: 10.1210/jc.2012-1269. Epub 2012 Jun 28. J Clin Endocrinol Metab. 2012. PMID: 22745248
The BRAF(V600E) mutation is an independent, poor prognostic factor for the outcome of patients with low-risk intrathyroid papillary thyroid carcinoma: single-institution results from a large cohort study.
Elisei R, Viola D, Torregrossa L, Giannini R, Romei C, Ugolini C, Molinaro E, Agate L, Biagini A, Lupi C, Valerio L, Materazzi G, Miccoli P, Piaggi P, Pinchera A, Vitti P, Basolo F. Elisei R, et al. Among authors: viola d. J Clin Endocrinol Metab. 2012 Dec;97(12):4390-8. doi: 10.1210/jc.2012-1775. Epub 2012 Oct 12. J Clin Endocrinol Metab. 2012. PMID: 23066120
196 results